Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$5.3 million.

  • Gain Therapeutics' Profit After Tax fell 1780.51% to -$5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.4 million, marking a year-over-year increase of 924.41%. This contributed to the annual value of -$20.4 million for FY2024, which is 833.65% up from last year.
  • As of Q3 2025, Gain Therapeutics' Profit After Tax stood at -$5.3 million, which was down 1780.51% from -$5.8 million recorded in Q2 2025.
  • Gain Therapeutics' Profit After Tax's 5-year high stood at -$2.5 million during Q1 2021, with a 5-year trough of -$8.1 million in Q2 2024.
  • Moreover, its 5-year median value for Profit After Tax was -$4.7 million (2021), whereas its average is -$4.7 million.
  • As far as peak fluctuations go, Gain Therapeutics' Profit After Tax crashed by 55457.15% in 2021, and later soared by 2866.23% in 2025.
  • Quarter analysis of 5 years shows Gain Therapeutics' Profit After Tax stood at -$3.2 million in 2021, then crashed by 45.17% to -$4.7 million in 2022, then decreased by 1.06% to -$4.7 million in 2023, then grew by 20.23% to -$3.8 million in 2024, then tumbled by 40.23% to -$5.3 million in 2025.
  • Its Profit After Tax was -$5.3 million in Q3 2025, compared to -$5.8 million in Q2 2025 and -$4.5 million in Q1 2025.